The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS: Exane Raises M&S; HSBC Ups Diploma To Buy

Fri, 12th Feb 2021 09:33

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

----------

FTSE 100

----------

RBC REINITIATES LONDON STOCK EXCHANGE WITH 'OUTPERFORM' - PRICE TARGET 11,500 PENCE

----------

KEPLER CHEUVREUX RAISES RELX PRICE TARGET TO 2,075 (1,960) PENCE - 'BUY'

----------

BARCLAYS RAISES RELX PRICE TARGET TO 2,090 (2,070) PENCE - 'OVERWEIGHT'

----------

BERENBERG RAISES COMPASS GROUP PRICE TARGET TO 1,600 (1,425) PENCE - 'BUY'

----------

BERENBERG RAISES WHITBREAD PRICE TARGET TO 3,600 (2,500) PENCE - 'BUY'

----------

BERENBERG RAISES INTERCONTINENTAL HOTELS TARGET TO 4,500 (4,000) PENCE - 'HOLD'

----------

MORGAN STANLEY CUTS GLAXOSMITHKLINE PRICE TARGET TO 1,580 (1,665) PENCE - 'EQUAL-WEIGHT'

----------

MORGAN STANLEY INITIATES FERGUSON WITH 'EQUAL-WEIGHT' - TARGET 9,060 PENCE

----------

DEUTSCHE BANK RAISES COCA-COLA HBC PRICE TARGET TO 2,900 (2,800) PENCE - 'BUY'

----------

GOLDMAN RAISES COCA-COLA HBC PRICE TARGET TO 2,700 (2,670) PENCE - 'BUY'

----------

JEFFERIES RAISES COCA-COLA HBC PRICE TARGET TO 2,800 (2,750) PENCE - 'BUY'

----------

FTSE 250

----------

EXANE RAISES MARKS & SPENCER TO 'OUTPERFORM' ('NEUTRAL') - PRICE TARGET 165 (140) PENCE

----------

BERENBERG RAISES SSP GROUP PRICE TARGET TO 370 (335) PENCE - 'BUY'

----------

BERENBERG CUTS TUI PRICE TARGET TO 175 (250) PENCE - 'SELL'

----------

BERENBERG CUTS CARNIVAL TO 'SELL' ('HOLD') - TARGET 1,000 (800) PENCE

----------

CREDIT SUISSE RAISES WIZZ AIR PRICE TARGET TO 5,788 (4,889) PENCE - 'OUTPERFORM'

----------

CREDIT SUISSE RAISES EASYJET PRICE TARGET TO 1,032 (842) PENCE - 'OUTPERFORM'

----------

LIBERUM RAISES ROYAL MAIL PRICE TARGET TO 480 (320) PENCE - 'HOLD'

----------

DEUTSCHE BANK RAISES ROYAL MAIL PRICE TARGET TO 680 (550) PENCE - 'BUY'

----------

BERNSTEIN RAISES ROYAL MAIL PRICE TARGET TO 400 (310) PENCE - 'MARKET-PERFORM'

----------

JPMORGAN RAISES ROYAL MAIL PRICE TARGET TO 641 (568) PENCE - 'OVERWEIGHT'

----------

UBS RAISES REDROW PRICE TARGET TO 885 (750) PENCE - 'BUY'

----------

JEFFERIES RAISES CRANSWICK PRICE TARGET TO 3,700 (3,600) PENCE - 'HOLD'

----------

JPMORGAN CUTS LANCASHIRE HOLDINGS PRICE TARGET TO 830 (900) PENCE - 'OVERWEIGHT'

----------

MORGAN STANLEY RAISES DRAX GROUP TARGET TO 400 (300) PENCE - 'EQUAL-WEIGHT'

----------

JPMORGAN RAISES VICTREX PRICE TARGET TO 2,150 (2,000) PENCE - 'NEUTRAL'

----------

DEUTSCHE BANK RAISES POLYPIPE PRICE TARGET TO 653 (602) PENCE - 'BUY'

----------

HSBC RAISES DIPLOMA TO 'BUY' ('HOLD') - TARGET 2,705 (1,680) PENCE

----------

OTHER MAIN MARKET AND AIM

----------

MORGAN STANLEY INITIATES BREEDON WITH 'OVERWEIGHT' - TARGET 114 PENCE

----------

PEEL HUNT RAISES HELICAL TO 'BUY' ('ADD') - TARGET 425 (450) PENCE

----------

CREDIT SUISSE RAISES RYANAIR PRICE TARGET TO 17.91 (17.23) EUR - 'OUTPERFORM'

----------

GOLDMAN CUTS TED BAKER PRICE TARGET TO 100 (130) PENCE - 'NEUTRAL'

----------

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.